Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000277.1(PAH):c.1208C>T (p.Ala403Val)

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA273106

92731 (ClinVar)

Gene: PAH

Condition: phenylketonuria

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: e8a0e1ef-d616-4dfe-a24e-30a901afa80f

Approved on: 2018-08-10

Published on: 2019-04-05

HGVS expressions

NM_000277.1:c.1208C>T

NM_000277.1(PAH):c.1208C>T (p.Ala403Val)

NC_000012.12:g.102840507G>A

CM000674.2:g.102840507G>A

NC_000012.11:g.103234285G>A

CM000674.1:g.103234285G>A

NC_000012.10:g.101758415G>A

NG_008690.1:g.82096C>T

NG_008690.2:g.122904C>T

NM_000277.2:c.1208C>T

NM_001354304.1:c.1208C>T

NM_000277.3:c.1208C>T

ENST00000307000.7:c.1193C>T

ENST00000551114.2:n.870C>T

ENST00000553106.5:c.1208C>T

ENST00000635477.1:n.312C>T

ENST00000635528.1:n.723C>T

Pathogenic

PM3_Very Strong PS3 PP4_Moderate

PP3 PM5 PM2

Evidence Links 3

Expert Panel

Phenylketonuria VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Phenylketonuria VCEP

PAH-specific ACMG/AMP criteria applied: PP4_Moderate: Seen on 3 PKU alleles, BH4 deficiency was ruled out. Upgraded per ClinGen Metabolic WG. (PMID:8268925); PM3_VeryStrong: A403V found with 4 pathogenic variants . Upgraded per ClinGen SVI workgroup. (PMID:9429153); PS3: In vitro A403V mutant protein activity was ~43% wt. (PMID:21820508). In summary this variant meets criteria to be classified as pathogenic for phenylketonuria in an autosomal recessive manner based on the ACMG/AMP criteria applied as specified by the PAH Expert Panel: (PP4_Moderate, PM3_VeryStrong, PS3).

PM3_Very Strong

A403V found with 4 pathogenic variants . Upgraded per ClinGen SVI workgroup.

A403V found in 13 Polish patients in trans with 4 different known pathogenic variants. R408W, R158Q, P281L, IVS10. PubMed:9429153

PS3

In vitro A403V mutant protein activity was ~43% wt.

We reproduced a full-length wild-type protein and seven natural full-length PAH variants (p.A403V), and analyzed their biochemical and biophysical behavior. The residual activity of the mutant PAH enzyme, expressed as a percentage of wild-type enzyme activity, was 43± 4% (p.A403V). Using confocal microscopy with the number and brightness technique, we studied the effect of BH4 addition directly in living human cells expressing wild-type PAH or p.A403V. Our results demonstrate that BH4 addition promotes re-establishment of the oligomerization equilibrium, thus indicating that the dimer-to-tetramer shift in pA403V plays a key role in BH4 responsiveness. PubMed:21820508

PP4_Moderate

Seen on 3 PKU alleles, BH4 deficiency was ruled out. Upgraded per ClinGen Metabolic WG.

53 patients with persistently elevated blood levels of phenylalanine who met the differential criteria for PAH deficiency. A403V was found on 3 alleles. All patients were presenting with blood phenylalanine levels persistently above 150 /umol/l, and diagnosis of PAH deficiency was made when other potential causes of hyperphenylalaninemia had been ruled out. The criteria for inclusion were: normal serum tyrosine, normal urinary excresion of biopterin and neopterin, and no indication of acquired hyperphenylalaninemia. PubMed:8268925

PP3

Conflicting predictions: tolerated in SIFT, deleterious in PolyPhen2, MutationTaster

PM5

No other reported variants in this codon

PM2

MAF= 0.00502 in gnomAD

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.